ALOPECIA AREATA

This study tests if dupilumab, a drug already used for eczema and asthma, can help children ages 6 to 17 with moderate to severe alopecia areata regrow hair. About 76 kids will receive either dupilumab or a placebo for 48 weeks, then all can get the real drug for another 48 weeks…

This study follows 850 people with alopecia areata who are taking the medication ritlecitinib. Researchers want to see how much hair regrows over 24 weeks and how patients feel during treatment. The goal is to understand how well the drug works outside of a controlled clinical tr…

This study tests a drug called deuruxolitinib in teens aged 12 to 17 with severe alopecia areata, a condition causing significant scalp hair loss. Participants must have at least 50% hair loss and will receive either the drug or a placebo for 24 weeks, followed by an open-label p…

This study tests whether transplanting healthy gut bacteria (microbiota transplant therapy) can help people with moderate to severe alopecia areata, an autoimmune disease that causes patchy or total hair loss. Researchers will give 40 adults a treatment to change their gut bacter…

This study tests a daily pill called upadacitinib for people with severe alopecia areata, a condition where the immune system attacks hair follicles, causing significant hair loss. About 123 adults and teens in Japan with at least 25% scalp hair loss will take either the drug or …

This study tests a new drug called LAD603 for adults with severe to very severe alopecia areata, a condition causing major hair loss. About 136 participants will receive either the drug or a placebo to see if it helps regrow hair and how safe it is. The goal is to measure changes…

This study tests if the drug ruxolitinib can help hair regrow in people with APECED, a rare immune disorder that causes severe hair loss. About 70 people aged 12 to 75 will take the pill twice daily for 8 months. The goal is to see if hair regrows and if other immune-related symp…

This study tests a daily pill called abrocitinib for people with Down syndrome who have eczema or patchy hair loss. About 56 participants will take the drug for up to 60 weeks to see if it safely controls their skin and scalp problems. The goal is to manage symptoms, not cure the…

This study tests an experimental drug called NXC736 for people with moderate to severe alopecia areata, a condition that causes patchy hair loss. About 73 adults aged 19 to 65 with stable hair loss for at least 6 months but less than 8 years will take the drug or a placebo for 12…

This study tests whether microneedling combined with either lactic acid, vitamin D3, or a steroid (triamcinolone) can help regrow hair in people with patchy alopecia areata. About 88 adults with small bald patches will receive one of the three combos. The goal is to see which mix…

This study tests an oral drug called upadacitinib for people with severe alopecia areata, a condition where the immune system attacks hair follicles, causing hair loss. About 1,500 adults and teens worldwide will take either the drug or a placebo daily for up to 160 weeks. The go…

This study tests an experimental drug called LY4005130 for people with severe alopecia areata, a condition causing significant hair loss. About 60 adults will receive either the drug or a placebo through an IV. The goal is to see if the drug can regrow hair and to check for side …

This early-stage study tests a new medicine called FB102 for people with severe to very severe alopecia areata, a condition causing major hair loss. About 32 adults will receive either FB102 or a placebo to see if the drug is safe and helps hair grow back. The main goal is to che…

This program offers early access to ritlecitinib, an experimental pill, for people with severe alopecia areata who have lost at least half of their scalp hair and have not improved with standard treatments. The goal is to provide a potential treatment option before the drug is fu…

This early-phase study tests a new drug, DR-01, in 80 adults with alopecia areata (patchy hair loss) or vitiligo (white patches on skin). The main goals are to check safety and see if the drug can improve hair regrowth or skin color. Participants are randomly assigned to differen…

This early-stage study tests whether injecting cyclosporine directly into bald patches can safely regrow hair in people with alopecia areata, an autoimmune condition causing patchy hair loss. About 12 adults with mild to moderate scalp hair loss will receive either the drug or a …

This study is testing a new laser (PALLAS) to treat skin diseases like vitiligo, psoriasis, alopecia areata, and atopic dermatitis. About 50 adults will receive UVB laser treatments twice a week for up to 3 months. The goal is to see if the laser improves the skin condition and i…

This study is a registry that will follow up to 1,500 teenagers aged 12-17 with severe alopecia areata, a condition causing hair loss. Researchers will collect information from routine doctor visits to better understand the disease, how it is managed, and what treatments work bes…

This study aims to understand how alopecia areata, vitiligo, and hidradenitis suppurativa affect the daily lives and well-being of teens and adults. Researchers will collect information from nearly 2,800 participants across multiple countries using questionnaires and skin assessm…

This observational study will follow about 5,000 adults with alopecia areata across North America. Researchers aim to learn more about how the disease develops, progresses, and is managed in real-world settings. Participants will continue their usual care while providing data thr…